These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33729079)

  • 21. Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
    Lang Y; Dong D; Wu B
    Clin Drug Investig; 2020 Dec; 40(12):1137-1146. PubMed ID: 33095408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness Analysis of Elective Neck Dissection in Patients With Clinically Node-Negative Oral Cavity Cancer.
    Acevedo JR; Fero KE; Wilson B; Sacco AG; Mell LK; Coffey CS; Murphy JD
    J Clin Oncol; 2016 Nov; 34(32):3886-3891. PubMed ID: 27551113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Grossi F; Costa F
    Clin Ther; 2020 May; 42(5):830-847. PubMed ID: 32354495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study.
    Pollom EL; Lee K; Durkee BY; Grade M; Mokhtari DA; Wahl DR; Feng M; Kothary N; Koong AC; Owens DK; Goldhaber-Fiebert J; Chang DT
    Radiology; 2017 May; 283(2):460-468. PubMed ID: 28045603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Tringale KR; Carroll KT; Zakeri K; Sacco AG; Barnachea L; Murphy JD
    J Natl Cancer Inst; 2018 May; 110(5):479-485. PubMed ID: 29126314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer.
    Lartigau EF; Tresch E; Thariat J; Graff P; Coche-Dequeant B; Benezery K; Schiappacasse L; Degardin M; Bondiau PY; Peiffert D; Lefebvre JL; Lacornerie T; Kramar A
    Radiother Oncol; 2013 Nov; 109(2):281-5. PubMed ID: 24262821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer.
    Paix A; Noel G; Falcoz PE; Levy P
    Radiother Oncol; 2018 Sep; 128(3):534-540. PubMed ID: 29706462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Economic Analysis of SC24 in Canada: A Randomized Study of SBRT Compared With Conventional Palliative RT for Spinal Metastases.
    Kerba M; Lourenco RA; Sahgal A; Cardet RF; Siva S; Ding K; Myrehaug SD; Masucci GL; Brundage M; Parulekar WR
    Int J Radiat Oncol Biol Phys; 2024 Jul; 119(4):1061-1068. PubMed ID: 38218455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer.
    Sher DJ; Parikh RB; Mays-Jackson S; Punglia RS
    Am J Clin Oncol; 2014 Jun; 37(3):215-21. PubMed ID: 23275277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases.
    Lester-Coll NH; Rutter CE; Bledsoe TJ; Goldberg SB; Decker RH; Yu JB
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):663-72. PubMed ID: 27055395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for up to 10 brain metastases.
    Lester-Coll NH; Dosoretz AP; Magnuson WJ; Laurans MS; Chiang VL; Yu JB
    J Neurosurg; 2016 Dec; 125(Suppl 1):18-25. PubMed ID: 27903191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Effectiveness Analysis of Stereotactic Ablative Radiation Therapy in Patients With Oligometastatic Cancer.
    Kumar A; Straka C; Courtney PT; Vitzthum L; Riviere P; Murphy JD
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1185-1194. PubMed ID: 33002541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial.
    Xin W; Ding H; Fang Q; Zheng X; Tong Y; Xu G; Yang G
    BMJ Open; 2020 Dec; 10(12):e038867. PubMed ID: 33371020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial.
    Wang H; Huang L; Gao P; Zhu Z; Ye W; Ding H; Fang L
    BMJ Open; 2020 Feb; 10(2):e030738. PubMed ID: 32051297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective, deformable registration analysis of the impact of PET-CT planning on patterns of failure in stereotactic body radiation therapy for recurrent head and neck cancer.
    Wang K; Heron DE; Flickinger JC; Rwigema JC; Ferris RL; Kubicek GJ; Ohr JP; Quinn AE; Ozhasoglu C; Branstetter BF
    Head Neck Oncol; 2012 Apr; 4():12. PubMed ID: 22515371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective.
    Zhou K; Li Y; Liao W; Zhang M; Bai L; Li Q
    Oral Oncol; 2020 Aug; 107():104754. PubMed ID: 32428689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
    Zargar M; McFarlane T; Chan KKW; Wong WWL
    Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cetuximab Plus Chemotherapy versus Chemotherapy Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
    Lang Y; Dong D
    Cancer Manag Res; 2020; 12():11383-11390. PubMed ID: 33204154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-utility of stereotactic radiation therapy
    Leung HWC; Chan ALF
    Oncotarget; 2017 Sep; 8(43):75568-75576. PubMed ID: 29088891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of PET-CT-guided management for locally advanced head and neck cancer.
    Smith AF; Hall PS; Hulme CT; Dunn JA; McConkey CC; Rahman JK; McCabe C; Mehanna H
    Eur J Cancer; 2017 Nov; 85():6-14. PubMed ID: 28881249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.